C
Contineum Therapeutics, Inc. (CTNM)
NMS – Real Time Price. Currency in USD
13.66
+0.01 (0.07%)
At close: May 12, 2026, 4:00 PM EDT
13.48
-0.18 (-1.32%)
After-hours: May 12, 2026, 4:57 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
13.66
+0.01 (0.07%)
At close: May 12, 2026, 4:00 PM EDT
13.48
-0.18 (-1.32%)
After-hours: May 12, 2026, 4:57 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 38.00 | 6.05 | 10 | |
| Quick ratio | 38.00 | 5.63 | 10 | |
| Debt to Equity | 0.03 | 0.30 | 9.0 | |
| Debt to Assets | 0.03 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | 50M | N/A | N/A | N/A |
| Gross Profit | -329K | 50M | -258K | -323K | -328K |
| Operating Income | -23M | 16M | -51M | -68M | -67M |
| Net Income | -24M | 23M | -42M | -60M | -58M |
| EBITDA | -22M | 16M | -51M | -68M | -67M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 22.35 | 5.5 |
| Next quarter | N/A | -1.9 | 1.0 |
| Current year | N/A | 17.64 | 5.0 |
| Next year | -68.04 | -10.23 | 1.0 |
| Weighted average score | 3.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 4.62 | 20.41 | -29.76 | 6.3 |
| Y/Y | 999 | 9.59 | 37.1 | -15.12 | 6.8 |
| 3y average | 632.67 | -44.73 | -2471.98 | -49.69 | 3.3 |
| 5y average | N/A | N/A | N/A | N/A | 1.0 |
| Weighted average score | 4.4 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $20.2M significantly exceed its total debt $7.0M, ensuring strong financial flexibility
Total current assets $253.0M exceed Total current liabilities $6.7M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$16.6M limits the company's ability to reinvest or pay down debt